34. 神経線維腫症
［臨床試験数：120，薬物数：182（DrugBank：72），標的遺伝子数：84，標的パスウェイ数：194］
Searched query = "Neurofibromatosis", "NF1", "von Recklinghausen disease", "NF2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03826940 (ClinicalTrials.gov) | February 19, 2019 | 23/1/2019 | From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 | Linking Inhibition From Molecular to Systems and Cognitive Levels: a Preclinical and Clinical Approach in Autism Spectrum Disorders and Neurofibromatosis. | Autism Spectrum Disorder;Neurofibromatosis 1 | Drug: Lovastatin 60 MG;Drug: Placebos | University of Coimbra | NULL | Recruiting | 16 Years | 65 Years | All | 30 | N/A | Portugal |
| 2 | EUCTR2016-005022-10-DE (EUCTR) | 13/02/2018 | 09/11/2017 | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Improvement of synaptic plasticity and cognitive function in RAS pathway disorders | Noonan Syndrom and Neurofibromatosis Type 1 MedDRA version: 20.0;Level: PT;Classification code 10029748;Term: Noonan syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 20.0;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Not possible to specify | Product Name: Lovastatin INN or Proposed INN: Lovastatin Other descriptive name: LOVASTATIN Product Name: Lamotrigin beta INN or Proposed INN: Lamotrigin | Technische Universität München, Fakultät für Medizin | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 30 | Phase 2 | Germany | ||
| 3 | NCT02964884 (ClinicalTrials.gov) | November 2016 | 9/11/2016 | Interventions for Reading Disabilities in NF1 | Neurobiology and Treatment of Reading Disability in NF1 | Neurofibromatosis Type 1;Learning Disability;Reading Disability;NF1 | Drug: Lovastatin;Behavioral: reading tutoring intervention;Drug: Placebo Oral Tablet;Behavioral: Other Academic sham tutoring | Vanderbilt University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Recruiting | 8 Years | 20 Years | All | 120 | Phase 2 | United States |
| 4 | NCT00352599 (ClinicalTrials.gov) | September 2009 | 13/7/2006 | Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) | Neurofibromatosis 1 | Drug: Lovastatin;Drug: placebo pill | University of California, Los Angeles | NULL | Completed | 10 Years | 50 Years | Both | 44 | Phase 1 | United States |
| 5 | NCT00853580 (ClinicalTrials.gov) | July 2009 | 23/2/2009 | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 | Neurofibromatosis Type 1 | Drug: Lovastatin ™;Device: placebo | University of Alabama at Birmingham | Boston Children's Hospital;Children's Hospital of Philadelphia;Children's National Research Institute;Children's Hospital Medical Center, Cincinnati;National Cancer Institute (NCI);University of Chicago;University of Utah;Washington University School of Medicine;Sydney Children's Hospitals Network;University of Texas Southwestern Medical Center | Completed | 8 Years | 15 Years | All | 146 | Phase 2 | United States;Australia |